Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab in Metastatic Hormone-sensitive Prostate Cancer
NCT03879122Phase 3Unknown
- Sponsor
- SOGUG
- Start
- Feb 2019
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in prostate cancer (PCa) (3 arms), sponsored by SOGUG. Primary endpoint: Overall Survival at 2 years. Status: unknown.
02
Drugs
nivolumabipilimumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03879122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03879122.